Understanding T cell immunity in adult T-cell leukemia/lymphoma
Official title: Functional state of CD8+ T cell immunity in adult T-cell leukemia/lymphoma
Funded at Albert Einstein College of Medicine · NIH-11066547 · Data updated 2026-11-12
This study is looking at how the immune system, specifically certain T cells, reacts in people with adult T-cell leukemia/lymphoma (ATLL) in North America compared to Japan, with the goal of finding better treatments to help patients feel better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | April 4, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $196,350 |
| NIH project number | 5R21CA290322-02 |
| Project ID | NIH-11066547 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with adult T-cell leukemia/lymphoma, particularly those of Caribbean descent living in North America.
✕Less likely to help
Patients with other types of leukemia or those not diagnosed with adult T-cell leukemia/lymphoma may not benefit from this research.
What this research studies
This research investigates the immune response of CD8+ T cells in patients with adult T-cell leukemia/lymphoma (ATLL), a severe condition linked to the human T-lymphotropic virus-1 (HTLV-1). The study aims to explore the differences in clinical presentation and immune characteristics between ATLL cases in North America and Japan. By enhancing our understanding of how ATLL cells evade the immune system, the research seeks to develop new therapeutic strategies that could improve patient outcomes. The approach includes examining the functional state of T cells and their ability to respond to the disease effectively.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with adult T-cell leukemia/lymphoma.
How similar studies have gone: Previous research has shown promise in enhancing T cell responses in similar hematological malignancies, indicating potential for success in this area.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Ye, Bihui Hilda — Albert Einstein College of Medicine
- Study coordinator: Ye, Bihui Hilda
Related research
Other NIH-funded projects on the same topics.
-
Bone marrow grafting and cellular therapies for leukemia and lymphoma
A program at Stanford aims to improve bone marrow transplantation and newer cellular therapies to treat blood cancers like leukemia and lymphoma.
-
Inhibiting T-cell Signaling to Treat Adult ATLL
A study to test whether blocking T-cell receptor signaling can help treat adult T-cell leukemia/lymphoma caused by HTLV-1, potentially improving outcomes for patients.
-
Understanding EP300 deficiency in ATLL in adults
This grant explores how loss of EP300 affects an aggressive adult T-cell cancer (ATLL) to identify new ways to help patients.
-
3D gene switches in leukemia and lymphoma
Researchers will map and try to block 3D gene-control hubs that help T-cell leukemia and lymphoma cells grow, aiming to find new ways to help people with these cancers.
-
Improving bone marrow transplants and cell therapies for leukemia and lymphoma
New cell-based treatments and transplant methods aim to make bone marrow transplants safer and help people with leukemia or lymphoma avoid relapse.
-
Targeting T-cell Signals for Adult T-cell Leukemia Lymphoma
This project explores new ways to treat adult T-cell leukemia lymphoma by blocking specific signals within cancer cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.